CECCHI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.689
EU - Europa 4.377
AS - Asia 821
AF - Africa 19
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 10.915
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.660
PL - Polonia 1.554
RU - Federazione Russa 1.200
IE - Irlanda 434
SE - Svezia 363
IT - Italia 323
SG - Singapore 214
CN - Cina 174
HK - Hong Kong 172
UA - Ucraina 141
DE - Germania 135
IN - India 96
GB - Regno Unito 95
JO - Giordania 80
FI - Finlandia 60
VN - Vietnam 55
CA - Canada 27
ES - Italia 25
FR - Francia 13
NL - Olanda 10
TR - Turchia 10
CI - Costa d'Avorio 9
RO - Romania 8
SC - Seychelles 7
CH - Svizzera 6
IR - Iran 5
JP - Giappone 5
KR - Corea 5
BE - Belgio 4
BR - Brasile 3
PH - Filippine 3
CL - Cile 2
EU - Europa 2
LT - Lituania 2
MX - Messico 2
TN - Tunisia 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
DK - Danimarca 1
ID - Indonesia 1
MU - Mauritius 1
NO - Norvegia 1
PK - Pakistan 1
PT - Portogallo 1
Totale 10.915
Salva come PNG Salva come JPEG
Città #
Warsaw 1.554
Santa Clara 885
Fairfield 836
Dublin 433
Ashburn 391
Woodbridge 361
Seattle 338
Cambridge 335
Chandler 320
Houston 286
Wilmington 264
Jacksonville 243
Singapore 165
Ann Arbor 127
Princeton 103
Lawrence 99
Altamura 95
Beijing 90
Hong Kong 83
Mumbai 83
Boston 79
Florence 64
Dong Ket 48
Boardman 42
Buffalo 41
Medford 40
San Diego 40
Moscow 39
Shanghai 25
Norwalk 21
New York 18
Barcelona 17
Munich 14
Ottawa 13
Phoenix 13
Toronto 12
West Jordan 12
Los Angeles 11
Rome 11
Abidjan 9
Andover 8
Frankfurt Am Main 8
Hillsboro 8
Milan 8
Auburn Hills 7
Falls Church 7
Izmir 7
London 7
Yubileyny 6
Catania 5
Mykolayiv 5
Prato 5
Seoul 5
Siena 5
Verona 5
Bern 4
Bologna 4
Brussels 4
Lappeenranta 4
Madrid 4
Nanjing 4
Salerno 4
Timisoara 4
Wuhan 4
Zhengzhou 4
Calenzano 3
Chiswick 3
Council Bluffs 3
Genoa 3
Guangzhou 3
Kent 3
Kilburn 3
Nagoya 3
Quezon City 3
Redwood City 3
Saint Petersburg 3
St Petersburg 3
Utrecht 3
Washington 3
Aguascalientes 2
Bengaluru 2
Canosa di Puglia 2
Chennai 2
Craiova 2
Dearborn 2
Duncan 2
Fiano Romano 2
Gatchina 2
Gloucester 2
Gävle 2
Hefei 2
Helsinki 2
Kish 2
Laurel 2
Montepulciano Stazione 2
Murcia 2
Naples 2
Nerviano 2
Omsk 2
Palizzi Marina 2
Totale 7.880
Salva come PNG Salva come JPEG
Nome #
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. 256
Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. 251
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. 250
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils 236
β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy 190
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 185
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy 180
Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations 179
Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care 167
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy 166
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study 160
Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil 158
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy 155
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy 151
Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment 144
An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy 140
MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol 139
Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy 139
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy 137
Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy 135
Malattia di Anderson-Fabry 135
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. 134
Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives 132
Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy 132
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 132
International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM) 131
HYPERTROPHIC CARDIOMYOPATHY 130
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe) 129
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. 128
Beta-Blockers for Prevention of Exercise-induced Left Ventricular Outflow Obstruction in Patients with Hypertrophic Cardiomyopathy 124
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. 122
Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. 121
ARRHYTHMIAS ASSOCIATED WITH HYPERTROPHIC CARDIOMYOPATHY 119
Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C 112
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy 112
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. 109
Echocardiographic features of right ventricular infarction. 109
European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology 107
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. 106
THE ITALIAN REGISTRY FOR HYPERTROPHIC CARDIOMYOPATHY: A NATIONWIDE SURVEY 106
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy 106
CLINICAL PROFILE OF STROKE IN 900 PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 105
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression 104
IMPACT OF ATRIAL FIBRILLATION ON THE CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY 103
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy 103
Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy 102
Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. 102
Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®) 102
Right ventricular infarction: clinical, hemodynamic, mono- and two-dimensional echocardiographic features. 101
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal 101
MAXIMUM LEFT VENTRICULAR THICKNESS AND RISK OF SUDDEN DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 98
RISK OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY ASSESSED BY SIGNAL AVERAGED P WAVE DURATION 98
RELEVANCE OF CORONARY MICROVASCULAR FLOW IMPAIRMENT TO LONG TERM REMODELING AND SYSTOLIC DYSFUNCTION IN HYPERTROPHIC CARDIOMYOPATHY 98
Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in Tuscany 96
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy 95
EPIDEMIOLOGY OF HYPERTROPHIC CARDIOMYOPATHY-RELATED DEATH: REVISITED IN A LARGE NON- REFERRAL-BASED PATIENT POPULATION 95
The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy 95
Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy 94
Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy 93
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy 92
Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy 92
HYPERTROPHIC CARDIOMYOPATHY IN TUSCANY: CLINICAL COURSE AND OUTCOME IN AN UNSELECTED REGIONAL POPULATION 91
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy 90
THE NEED FOR EUROPEAN REGISTRIES IN INHERITED CARDIOMYOPATHIES 89
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy 89
TRANSIENT ASYMMETRIC VENTRICULAR SEPTAL HYPERTROPHY IN THE NEWBORN UNASSOCIATED WITH MATERNAL DIABETES 88
'End-stage' hypertrophic cardiomyopathy: from mystery to model 85
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy) 84
Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy 83
Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy 83
Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy 83
Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening 83
Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy 80
EFFECT OF VERAPAMIL ON ABSOLUTE MYOCARDIAL BLOOD FLOW IN HYPERTROPHIC CARDIOMYOPATHY 78
PROGNOSTIC VALUE OF NON-SUSTAINED VENTRICULAR TACHYCARDIA AND THE POTENTIAL ROLE OF AMIODARONE TREATMENT IN HYPERTROPHIC CARDIOMIYOPATHY: ASSESSMENT IN AN UNSELECTED NON-REFERRAL BASEDE PATIENT POPULATION 78
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team 77
Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy 76
Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy 76
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. 74
RISK FACTORS AND STRATIFICATION FOR SUDDEN CARDIAC DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 73
CLINICAL UTILITY AND SAFETY OF EXERCISE TESTING IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 73
Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy 72
An expert consensus document on the management of cardiovascular manifestations of Fabry disease 71
Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy 68
Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy 67
Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanism and clinical consequences 66
CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY IN A NON SELECTED POPULATION. EXPERIENCE OF THE ITALIAN MULTICENTER CARDIOMYOPATHY STUDY 65
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy 65
CARDIOMIOPATIA IPERTROFICA 65
Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes 65
NEW CONCEPTS IN HYPERTROPHIC CARDIOMYOPATHIES 64
CHARACTERISTICS OF MYOCARDIAL HYPERTROPHY IN FRIEDREICH'S ATAXIA. CLINICO-INSTRUMENTAL STUDY IN 10 PATIENTS AND REVIEW OF THE LITERATURE 62
Cardiomiopatie, Miocarditi e Pericarditi 62
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions 61
DIASTOLIC TIME INTERVALS BEFORE AN AFTER NADOLOL IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 60
Surgical myectomy versus percutaneous alcohol ablation for obstructive hypertrophic cardiomyopathy: will there ever be a randomized trial 60
LONG-TERM OUTCOME OF PATIENTS WITH HYPERTROPHIC CARIOMYOPATHY SUCCESSFULLY RESUSCITATED AFTER CARDIAC ARREST 56
Stage-specific therapy for hypertrophic cardiomyopathy 54
THE EPIDEMIOLOGIC EVOLUTION AND PRESENT PERCEPTION OF HYPERTROPHIC CARDIOMYOPATHY 53
Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis 52
Totale 10.844
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.907
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.018 0 0 0 0 247 269 326 394 296 191 240 55
2020/20211.775 156 180 96 215 86 180 80 156 139 281 66 140
2021/2022723 32 33 66 28 29 43 29 46 46 36 151 184
2022/20231.694 169 272 89 95 131 315 245 69 220 14 61 14
2023/2024590 23 72 118 36 38 78 18 109 15 32 20 31
2024/20252.716 165 481 267 680 1.123 0 0 0 0 0 0 0
Totale 11.005